Comparison of incidences of graft-versus-host disease in subgroups of patients treated by bulk dose regimen
| . | <1.5 × 108 (n = 11) . | ≥1.5 × 108 (n = 11) . |
|---|---|---|
| Relapse stage | ||
| Cytogenetic | 2 | 5 |
| Hematologic–CP | 8 | 5 |
| Hematologic–AP | 1 | 1 |
| Complete remission | 6 (54%) | 9 (81%) |
| GVHD: | ||
| Acute | ||
| Grades 0-1 | 6 | 6 |
| Grade 2 | 1 | 3 |
| Grades 3-4 | 4 | 2 |
| Chronic | ||
| None/limited | 6 | 5 |
| Extensive | 4 | 6 |
| . | <1.5 × 108 (n = 11) . | ≥1.5 × 108 (n = 11) . |
|---|---|---|
| Relapse stage | ||
| Cytogenetic | 2 | 5 |
| Hematologic–CP | 8 | 5 |
| Hematologic–AP | 1 | 1 |
| Complete remission | 6 (54%) | 9 (81%) |
| GVHD: | ||
| Acute | ||
| Grades 0-1 | 6 | 6 |
| Grade 2 | 1 | 3 |
| Grades 3-4 | 4 | 2 |
| Chronic | ||
| None/limited | 6 | 5 |
| Extensive | 4 | 6 |
GVHD, graft-versus-host disease.
Lymphocyte doses ranged from <1.5 × 108/kg to >1.5 × 108/kg.